The global ambulatory infusion centers market size is calculated at USD 50.63 billion in 2025 and is forecasted to reach around USD 126.27 billion by 2034, accelerating at a CAGR of 10.69% from 2025 to 2034. The North America market size surpassed USD 26.54 billion in 2024 and is expanding at a CAGR of 10.78% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Ambulatory Infusion Centers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Ambulatory Infusion Centers Market, by Therapy Type
8.1.1. Anti-infective Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Hydration Therapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Immunoglobulin Therapy
8.1.4.1. Market Revenue and Forecast
8.1.5. Biological Therapy
8.1.5.1. Market Revenue and Forecast
8.1.6. Enteral and Parenteral Nutrition
8.1.6.1. Market Revenue and Forecast
8.1.7. Others (e.g., corticosteroids, pain management infusions)
8.1.7.1. Market Revenue and Forecast
9.1. Ambulatory Infusion Centers Market, by Application
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast
9.1.2. Autoimmune Disorders
9.1.2.1. Market Revenue and Forecast
9.1.3. Neurological Disorders
9.1.3.1. Market Revenue and Forecast
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast
9.1.5. Gastrointestinal Disorders
9.1.5.1. Market Revenue and Forecast
9.1.6. Immune Deficiencies
9.1.6.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. Ambulatory Infusion Centers Market, by End-User
10.1.1. Hospital-Affiliated Infusion Centers
10.1.1.1. Market Revenue and Forecast
10.1.2. Physician Office Infusion Centers (POICs)
10.1.2.1. Market Revenue and Forecast
10.1.3. Standalone/Independent Infusion Centers
10.1.3.1. Market Revenue and Forecast
10.1.4. Home Infusion Service Providers (with ambulatory setups)
10.1.4.1. Market Revenue and Forecast
11.1. Ambulatory Infusion Centers Market, by Payor Type
11.1.1. Commercial Insurance
11.1.1.1. Market Revenue and Forecast
11.1.2. Medicare
11.1.2.1. Market Revenue and Forecast
11.1.3. Medicaid
11.1.3.1. Market Revenue and Forecast
11.1.4. Out-of-Pocket / Self-Pay
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type
12.1.2. Market Revenue and Forecast, by Application
12.1.3. Market Revenue and Forecast, by End-User
12.1.4. Market Revenue and Forecast, by Payor Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type
12.1.5.2. Market Revenue and Forecast, by Application
12.1.5.3. Market Revenue and Forecast, by End-User
12.1.5.4. Market Revenue and Forecast, by Payor Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type
12.1.6.2. Market Revenue and Forecast, by Application
12.1.6.3. Market Revenue and Forecast, by End-User
12.1.6.4. Market Revenue and Forecast, by Payor Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type
12.2.2. Market Revenue and Forecast, by Application
12.2.3. Market Revenue and Forecast, by End-User
12.2.4. Market Revenue and Forecast, by Payor Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type
12.2.5.2. Market Revenue and Forecast, by Application
12.2.5.3. Market Revenue and Forecast, by End-User
12.2.5.4. Market Revenue and Forecast, by Payor Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type
12.2.6.2. Market Revenue and Forecast, by Application
12.2.6.3. Market Revenue and Forecast, by End-User
12.2.6.4. Market Revenue and Forecast, by Payor Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type
12.2.7.2. Market Revenue and Forecast, by Application
12.2.7.3. Market Revenue and Forecast, by End-User
12.2.7.4. Market Revenue and Forecast, by Payor Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type
12.2.8.2. Market Revenue and Forecast, by Application
12.2.8.3. Market Revenue and Forecast, by End-User
12.2.8.4. Market Revenue and Forecast, by Payor Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type
12.3.2. Market Revenue and Forecast, by Application
12.3.3. Market Revenue and Forecast, by End-User
12.3.4. Market Revenue and Forecast, by Payor Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type
12.3.5.2. Market Revenue and Forecast, by Application
12.3.5.3. Market Revenue and Forecast, by End-User
12.3.5.4. Market Revenue and Forecast, by Payor Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type
12.3.6.2. Market Revenue and Forecast, by Application
12.3.6.3. Market Revenue and Forecast, by End-User
12.3.6.4. Market Revenue and Forecast, by Payor Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type
12.3.7.2. Market Revenue and Forecast, by Application
12.3.7.3. Market Revenue and Forecast, by End-User
12.3.7.4. Market Revenue and Forecast, by Payor Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type
12.3.8.2. Market Revenue and Forecast, by Application
12.3.8.3. Market Revenue and Forecast, by End-User
12.3.8.4. Market Revenue and Forecast, by Payor Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type
12.4.2. Market Revenue and Forecast, by Application
12.4.3. Market Revenue and Forecast, by End-User
12.4.4. Market Revenue and Forecast, by Payor Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type
12.4.5.2. Market Revenue and Forecast, by Application
12.4.5.3. Market Revenue and Forecast, by End-User
12.4.5.4. Market Revenue and Forecast, by Payor Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type
12.4.6.2. Market Revenue and Forecast, by Application
12.4.6.3. Market Revenue and Forecast, by End-User
12.4.6.4. Market Revenue and Forecast, by Payor Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type
12.4.7.2. Market Revenue and Forecast, by Application
12.4.7.3. Market Revenue and Forecast, by End-User
12.4.7.4. Market Revenue and Forecast, by Payor Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type
12.4.8.2. Market Revenue and Forecast, by Application
12.4.8.3. Market Revenue and Forecast, by End-User
12.4.8.4. Market Revenue and Forecast, by Payor Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type
12.5.2. Market Revenue and Forecast, by Application
12.5.3. Market Revenue and Forecast, by End-User
12.5.4. Market Revenue and Forecast, by Payor Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type
12.5.5.2. Market Revenue and Forecast, by Application
12.5.5.3. Market Revenue and Forecast, by End-User
12.5.5.4. Market Revenue and Forecast, by Payor Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type
12.5.6.2. Market Revenue and Forecast, by Application
12.5.6.3. Market Revenue and Forecast, by End-User
12.5.6.4. Market Revenue and Forecast, by Payor Type
13.1. Option Care Health
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. InfuCare Rx
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Coram CVS (now part of Option Care)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. KabaFusion
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. BioScrip (now part of Option Care)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Amerita (a PharMerica company)
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. United Infusion
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Soleo Health
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. PromptCare
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Paragon Healthcare
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description